DSRV.io · Enforcement-informed quality intelligence
DSRVDSRV.io
Browse by regulation5 articles · 5 high

21 CFR 211.100

Every DSRV article whose Regulatory Snapshot cites 21 CFR 211.100: the enforcement case behind it, the inspection exposure it created, and what the desk would do about it.

Inspection exposure across the set
In brief
What has FDA cited under 21 CFR 211.100?
5 DSRV articles cite 21 CFR 211.100. Enforcement cases behind them: Anthropic Managed Agents (July 2026 public beta) read against Purolea Cosmetics Lab FDA Warning Letter (April 2026); MCP 2026-07-28 release candidate; FDA Warning Letter to Purolea Cosmetics Lab (April 2026); FDA Warning Letter to Purolea Cosmetics Lab, April 2, 2026, CDER, CGMP/Adulterated/Unapproved New Drug; FDA Warning Letter 320-26-54, CMS Case 722736, to Yangzhou H&R Plastic Daily Chemical Co., Ltd., March 18, 2026; FDA Warning Letter 320-26-58 (CMS Case 722591) to Purolea Cosmetics Lab, April 2, 2026, the CDER letter citing AI-generated drug product specifications, procedures, and master production and control records issued without adequate quality-unit review. Inspection exposure across them: 5 high.
What does DSRV recommend for 21 CFR 211.100?
From the newest article (Your Next 483 Observation Is Running on a Timer): Defining the QU boundary, validation basis, and change-control wrapper around autonomous agent actions is the firm's job, not the vendor's — settle it before a scheduled agent fires. DSRV is decision support, not legal advice; verify against the official source each article names.
  1. 6 min readHigh exposurecited as a tag

    Your Next 483 Observation Is Running on a Timer

    Anthropic's July 2026 Managed Agents release ships scheduled autonomous runs and authenticated enterprise access. Pharma quality teams that have approved these capabilities without a QU review checkpoint built into the workflow architecture are building toward a Purolea-pattern inspection finding.

    Case
    Anthropic Managed Agents (July 2026 public beta) read against Purolea Cosmetics Lab FDA Warning Letter (April 2026)
    DSRV take
    Defining the QU boundary, validation basis, and change-control wrapper around autonomous agent actions is the firm's job, not the vendor's — settle it before a scheduled agent fires.
  2. 5 min readHigh exposurecited as a tag

    MCP Goes Stateless on July 28. For Pharma AI Teams, That Is a Change Control Event.

    The MCP protocol's July 28 release candidate introduces six breaking changes and deprecates three core primitives. For pharma teams running MCP-enabled tools, the deadline is a validation checkpoint and a documentation obligation under FDA's AI-CGMP enforcement precedent.

    Case
    MCP 2026-07-28 release candidate; FDA Warning Letter to Purolea Cosmetics Lab (April 2026)
    DSRV take
    Treat the July 28 protocol change like any infrastructure update in a validated environment: inventory MCP-enabled tools, confirm vendor SDK migration, and document the change-control decision before the deadline.
  3. 7 min readHigh exposurecited as a tag

    The AI Never Told Us: What FDA's First AI Warning Letter Really Means

    A Michigan homeopathic drug manufacturer used AI agents to generate SOPs, specifications, and production records. FDA's April 2026 warning letter drew the enforcement line the industry had been watching for.

    Case
    FDA Warning Letter to Purolea Cosmetics Lab, April 2, 2026, CDER, CGMP/Adulterated/Unapproved New Drug.
    DSRV take
    FDA is not creating a new AI standard. It is applying the existing one. QU review of AI-generated GMP documents is mandatory. Purolea is now the primary enforcement reference.
  4. 6 min readHigh exposurecited as a tag

    The Certificate of Analysis Is Not a Test

    FDA's March 2026 warning letter to Yangzhou H&R Plastic documented three co-occurring failures that define small OTC manufacturer inspection risk: batch release without identity testing, a quality unit with no structural independence, and zero process validation before commercial distribution.

    Case
    FDA Warning Letter 320-26-54, CMS Case 722736, to Yangzhou H&R Plastic Daily Chemical Co., Ltd., March 18, 2026.
    DSRV take
    The diagnostic question is not whether incoming materials are tested but whether the person signing incoming material releases has any organizational reason to approve them regardless of the data; if the QU Director also controls the budget that pays suppliers, the org chart is already a finding.
  5. 4 min readHigh exposurecited as a tag

    AI Wrote the Documents. FDA's Warning Letter Was Addressed to You.

    An April 2026 FDA warning letter cited a drug manufacturer for using AI to generate specifications, procedures, and production records without adequate quality-unit review. The compliance logic has not changed: under GMP, human accountability does not transfer to the tool.

    Case
    FDA Warning Letter 320-26-58 (CMS Case 722591) to Purolea Cosmetics Lab, April 2, 2026, the CDER letter citing AI-generated drug product specifications, procedures, and master production and control records issued without adequate quality-unit review.
    DSRV take
    AI changes the tool, not the owner: the decisive control is a defined review checkpoint that names the reviewer, states the criteria applied, and records what was checked in each AI-generated document, because a signature alone proves only that someone touched it.
Address this risk

Pressure-test your evidence before an inspector reads it

Bring the document that has to hold up under 21 CFR 211.100. DSRV maps the evidence, names the gaps, and routes judgment calls to human review. Controlled intake, no public file upload.

Apply for the Stability Pilot Ask The Vault about 21 CFR 211.100

Regulatory intelligence and interpretation, not legal advice. Verify against the official FDA or ICH source each article names.